Is AbbVie the Best Dividend King to Buy in September?

AbbVie has increased its dividend for 54 consecutive years, including its Abbott Laboratories legacy, and is positioned to continue dividend growth despite Humira's 2023 U.S. patent expiry. The company restored revenue and earnings growth through the $63 billion Allergan acquisition, licensing, and internally developed products, with Skyrizi and Rinvoq now leading growth. Management expects no significant patent expirations until the end of the decade, while pipeline assets including eczema candidate Zumilokibart, weight-loss candidate ABBV-295, and cancer drug ABBV-706 could support longer-term replacement growth.

Analysis

The relevant underwriting question is not dividend continuity but whether AbbVie can sustain post-Humira earnings power without progressively raising business-development spend. Skyrizi/Rinvoq concentration creates a favorable near-term operating-leverage setup: incremental immunology revenue carries materially higher margins than acquired-product sales, supporting both dividend coverage and deleveraging. The offset is payer concentration risk; intensified formulary competition, biosimilar-style net-price pressure, or safety-label changes in JAK inhibitors could impair the assumed revenue-to-EPS conversion well before patent expiry.

Botox provides diversification but also introduces a more discretionary exposure than the defensive-pharma framing implies. A softer consumer environment would pressure aesthetics volumes and mix, while therapeutic Botox faces reimbursement scrutiny; this makes ABBV less recession-insulated than JNJ despite superior current growth visibility. Conversely, successful late-stage pipeline assets should not be capitalized into base-case valuation until pivotal data and commercial differentiation are visible—early pipeline breadth is not equivalent to a replacement franchise.

Near term, this is unlikely to be a standalone catalyst absent immunology prescription, net-price, or guidance revisions. Over 1-3 months, the key read-through is whether management can maintain earnings guidance while funding pipeline acquisitions and dividend growth; over 6-18 months, relative performance versus JNJ should hinge on whether ABBV converts immunology growth into durable free cash flow rather than larger deal-related amortization and leverage. The contrarian risk is that income-focused ownership already prices the payout as a quasi-bond: a modest guidance reset could produce multiple compression disproportionate to the earnings miss.

Key Decisions for Investors

• Maintain, rather than add aggressively to, ABBV until the next earnings release validates Skyrizi/Rinvoq volume growth, net pricing, and full-year EPS guidance. Add only if immunology growth is intact and the stock underperforms on market volatility rather than on a guidance cut; thesis is falsified by a material reduction in immunology sales outlook or dividend coverage deterioration.
• Express the relative fundamental view through long ABBV / short JNJ only if ABBV's forward P/E discount to JNJ is at least 10% while immunology guidance remains unchanged. Target a 5-10% relative return over 6-12 months from higher ABBV earnings growth; exit if JNJ closes its growth gap through oncology upside or ABBV reports a safety, reimbursement, or net-price disruption.
• Use ABBV as a watch item for pipeline-driven upside, not a pre-data biotech trade: monitor pivotal-study timing, regulatory filings, and deal terms for future immunology and obesity assets. Initiate a tactical position only after independently verifiable efficacy and safety data establish differentiation; acquisition announcements alone are more likely to increase capital-allocation uncertainty than create immediate value.
• Avoid using HRL, WMT, NFLX, or NVDA as read-through trades from this item. Their inclusion is editorial rather than evidence of a shared earnings, competitive, or supply-chain catalyst.